RSS   Newsletter   Contact   Advertise with us

Galmed Pharma appoints Carol Brosgart to board

Staff Writer | New York, N.Y., USA | June 9, 2017
Galmed PharmaceuticalsJune 9, 2017, New York, N.Y., USA - Galmed Pharmaceuticals, a clinical-stage biopharmaceutical company, elects Carol L. Brosgart as a new Class I director to serve as a member of the board of directors until the close of the annual general meeting to be held in 2018.
Dr. Brosgart brings a vast array of clinical, policy and corporate experience to Galmed having held senior management positions with several leading pharmaceutical and life sciences companies.

Dr. Brosgart, as Vice President, Clinical Research at Gilead Sciences, oversaw the NDA, EU and global approvals and launches of Viread for HIV and Hepsera for Hepatitis B.

Recently, she served for eight years as a member of the board of directors of Tobira Therapeutics until it was acquired by Allergan in November 2016. She is also active in the public policy arena for AASLD and IDSA/HIVMA.

Dr. Brosgart is a member of the Executive Committee of the Forum for Collaborative Research (FCR) at the University of California, Berkeley and has served on both the Steering Committee of the FCR's Liver Forum, which is a leader in the field of collaborative research focused on NASH, and the FCR's HBV Forum, focused on cure research for Hepatitis B.

Dr. Brosgart has published widely in the field of chronic viral infections and liver disease and serves as a Clinical Professor of Medicine, Biostatistics and Epidemiology at the University of California San Francisco (UCSF).